CoChat

B cells and their cytokine activities implications in human diseases

Open access
Fillatreau, Simon · 2018 · Clinical Immunology
Cited by 68

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

B cells are the only cell type that can give rise to antibody-producing cells, and the only cell type whose selective depletion can, today, lead to an improvement of a wide range of immune-mediated inflammatory diseases, including disorders not primarily driven by autoantibodies. Here, I discuss this paradoxical observation, and propose that the capacity of B cells to act as cytokine-producing cells explains how they can control monocyte activity and subsequently disease pathogenesis. Together with current data on the effect of anti-CD20 B cell-depleting reagents in the clinic, this novel knowledge on B cell heterogeneity opens the way for novel safer and more efficient strategies to target B cells. The forthcoming identification of disease-relevant B cell subsets is awaited to permit their monitoring and specific targeting in a personalized medicine approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clim.2017.07.020

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 92

  1. Cunningham-Rundles, 2005, Molecular defects in T- and B-cell primary immunodeficiency diseases, Nat. Rev. Immunol., 5, 880, 10.1038/nri1713 · DOI · Paper page
  2. Gelfand, 2017, Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis, Neurotherapeutics, 10.1007/s13311-017-0557-4 · DOI · Paper page
  3. Link, 1977, Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis, Scand. J. Clin. Lab. Invest., 37, 397, 10.3109/00365517709091498 · DOI
  4. Fillatreau, 2007, B-cell function in CNS inflammatory demyelinating disease: a complexity of roles and a wealth of possibilities, Expert. Rev. Clin. Immunol., 3, 565, 10.1586/1744666X.3.4.565 · DOI
  5. Brandle, 2016, Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins, Proc. Natl. Acad. Sci. U. S. A., 113, 7864, 10.1073/pnas.1522730113 · DOI · Paper page
  6. Vermeulen, 2011, Identification of a novel autoantigen in inflammatory bowel disease by protein microarray, Inflamm. Bowel Dis., 17, 1291, 10.1002/ibd.21508 · DOI
  7. von Budingen, 2008, Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies, Eur. J. Immunol., 38, 2014, 10.1002/eji.200737784 · DOI · Paper page
  8. Ritchie, 2004, Comparative analysis of the CD19+ and CD138+ cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis, J. Immunol., 173, 649, 10.4049/jimmunol.173.1.649 · DOI
  9. Storch, 1998, Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination, Ann. Neurol., 43, 465, 10.1002/ana.410430409 · DOI · Paper page
  10. Genain, 1999, Identification of autoantibodies associated with myelin damage in multiple sclerosis, Nat. Med., 5, 170, 10.1038/5532 · DOI · Paper page
  11. Schluesener, 1987, A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease, J. Immunol., 139, 4016, 10.4049/jimmunol.139.12.4016 · DOI · Paper page
  12. Lalive, 2006, Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis, Proc. Natl. Acad. Sci. U. S. A., 103, 2280, 10.1073/pnas.0510672103 · DOI · Paper page
  13. Kappos, 2011, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet, 378, 1779, 10.1016/S0140-6736(11)61649-8 · DOI · Paper page
  14. Petereit, 2008, Rituximab in a patient with multiple sclerosis—effect on B cells, plasma cells and intrathecal IgG synthesis, Acta Neurol. Scand., 117, 399, 10.1111/j.1600-0404.2007.00958.x · DOI
  15. Barr, 2012, B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells, J. Exp. Med., 209, 1001, 10.1084/jem.20111675 · DOI · Paper page
  16. Molnarfi, 2013, MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies, J. Exp. Med., 210, 2921, 10.1084/jem.20130699 · DOI · Paper page
  17. Bar-Or, 2010, Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?, Ann. Neurol., 67, 452, 10.1002/ana.21939 · DOI · Paper page
  18. Miyazaki, 2014, A novel microRNA-132-sirtuin-1 axis underlies aberrant B-cell cytokine regulation in patients with relapsing-remitting multiple sclerosis [corrected], PLoS One, 9, e105421, 10.1371/journal.pone.0105421 · DOI · Paper page
  19. Li, 2015, Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy, Sci. Transl. Med., 7, 310ra166, 10.1126/scitranslmed.aab4176 · DOI · Paper page
  20. Ngo, 1999, Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen, J. Exp. Med., 189, 403, 10.1084/jem.189.2.403 · DOI · Paper page
  21. Krumbholz, 2006, Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment, Brain, 129, 200, 10.1093/brain/awh680 · DOI · Paper page
  22. Piccio, 2010, Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis, Arch. Neurol., 67, 707, 10.1001/archneurol.2010.99 · DOI · Paper page
  23. Cross, 2006, Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients, J. Neuroimmunol., 180, 63, 10.1016/j.jneuroim.2006.06.029 · DOI · Paper page
  24. El Behi, 2017, Adaptive human immunity drives remyelination in a mouse model of demyelination, Brain, 140, 967, 10.1093/brain/awx008 · DOI · Paper page
  25. Lino, 2016, Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases, Immunol. Rev., 269, 130, 10.1111/imr.12374 · DOI · Paper page
  26. Yoshizaki, 2012, Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions, Nature, 491, 264, 10.1038/nature11501 · DOI · Paper page
  27. Duddy, 2007, Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis, J. Immunol., 178, 6092, 10.4049/jimmunol.178.10.6092 · DOI · Paper page
  28. Iwata, 2011, Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells, Blood, 117, 530, 10.1182/blood-2010-07-294249 · DOI · Paper page
  29. Heine, 2014, Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts, Eur. J. Immunol., 44, 1615, 10.1002/eji.201343822 · DOI · Paper page
  30. Larousserie, 2006, Variable expression of Epstein-Barr virus-induced gene 3 during normal B-cell differentiation and among B-cell lymphomas, J. Pathol., 209, 360, 10.1002/path.1995 · DOI
  31. de Masson, 2015, CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease, Blood, 125, 1830, 10.1182/blood-2014-09-599159 · DOI · Paper page
  32. Hartung, 2010, Atacicept: targeting B cells in multiple sclerosis, Ther. Adv. Neurol. Disord., 3, 205, 10.1177/1756285610371146 · DOI · Paper page
  33. Correale, 2008, Helminth infections associated with multiple sclerosis induce regulatory B cells, Ann. Neurol., 64, 187, 10.1002/ana.21438 · DOI · Paper page
  34. Correale, 2007, Association between parasite infection and immune responses in multiple sclerosis, Ann. Neurol., 61, 97, 10.1002/ana.21067 · DOI · Paper page
  35. Carter, 2010, Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis, Drugs, 70, 1545, 10.2165/11204560-000000000-00000 · DOI
  36. Ireland, 2014, The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis, JAMA Neurol., 71, 1421, 10.1001/jamaneurol.2014.1472 · DOI
  37. Kala, 2010, B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis, Exp. Neurol., 221, 136, 10.1016/j.expneurol.2009.10.015 · DOI
  38. Miyazaki, 2014, Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations, Clin. Immunol., 151, 127, 10.1016/j.clim.2014.02.001 · DOI
  39. Grutzke, 2015, Fingolimod treatment promotes regulatory phenotype and function of B cells, Ann. Clin. Transl. Neurol., 2, 119, 10.1002/acn3.155 · DOI
  40. McInnes, 2017, Pathogenetic insights from the treatment of rheumatoid arthritis, Lancet, 389, 2328, 10.1016/S0140-6736(17)31472-1 · DOI · Paper page
  41. Brink, 2013, Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis, Arthritis Rheum., 65, 899, 10.1002/art.37835 · DOI · Paper page
  42. Rantapaa-Dahlqvist, 2003, Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis, Arthritis Rheum., 48, 2741, 10.1002/art.11223 · DOI · Paper page
  43. Iwaki-Egawa, 2005, Production of anti-CCP antibodies and matrix metalloproteinase-3 by human rheumatoid arthritis synovial tissues using SCID mice, Ann. Rheum. Dis., 64, 1094, 10.1136/ard.2004.032847 · DOI
  44. Vos, 2007, Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis, Arthritis Rheum., 56, 772, 10.1002/art.22400 · DOI · Paper page
  45. Doorenspleet, 2014, Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity, Ann. Rheum. Dis., 73, 756, 10.1136/annrheumdis-2012-202861 · DOI
  46. Silverman, 2003, Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy, Arthritis Rheum., 48, 1484, 10.1002/art.10947 · DOI · Paper page
  47. Keystone, 2009, Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies, Ann. Rheum. Dis., 68, 216, 10.1136/ard.2007.085787 · DOI · Paper page
  48. Wheater, 2011, Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis, Osteoporos. Int., 22, 3067, 10.1007/s00198-011-1607-0 · DOI
  49. Boumans, 2012, Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis, Ann. Rheum. Dis., 71, 108, 10.1136/annrheumdis-2011-200198 · DOI
  50. Rosengren, 2011, CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis, Rheumatology (Oxford), 50, 603, 10.1093/rheumatology/keq337 · DOI · Paper page
  51. Sellam, 2013, CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis, Arthritis Rheum., 65, 2253, 10.1002/art.38023 · DOI
  52. Hogan, 2012, Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab, Ann. Rheum. Dis., 71, 1888, 10.1136/annrheumdis-2011-201115 · doi:10.1136/annrheumdis-2011-201115
  53. Isaacs, 2013, Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis, Ann. Rheum. Dis., 72, 329, 10.1136/annrheumdis-2011-201117 · DOI · Paper page
  54. Emery, 2006, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial, Arthritis Rheum., 54, 1390, 10.1002/art.21778 · DOI · Paper page
  55. Emery, 2011, Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response, Ann. Rheum. Dis., 70, 2063, 10.1136/ard.2010.148015 · DOI
  56. Kuhn, 2006, Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis, J. Clin. Invest., 116, 961, 10.1172/JCI25422 · DOI · Paper page
  57. Cambridge, 2003, Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis, Arthritis Rheum., 48, 2146, 10.1002/art.11181 · DOI · Paper page
  58. Tak, 2008, Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study, Arthritis Rheum., 58, 61, 10.1002/art.23178 · DOI · Paper page
  59. van Vollenhoven, 2011, Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial, Arthritis Rheum., 63, 1782, 10.1002/art.30372 · DOI · Paper page
  60. Lal, 2011, Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment, Arthritis Rheum., 63, 3681, 10.1002/art.30596 · DOI
  61. Cambridge, 2014, The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment, J. Autoimmun., 50, 67, 10.1016/j.jaut.2013.12.002 · DOI
  62. Yasuda, 1998, Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proc. Natl. Acad. Sci. U. S. A., 95, 3597, 10.1073/pnas.95.7.3597 · DOI · Paper page
  63. Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X · DOI · Paper page
  64. Chiu, 2017, Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis, Expert. Opin. Biol. Ther., 17, 119, 10.1080/14712598.2017.1263614 · DOI
  65. Meednu, 2016, Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis, Arthritis Rheum., 68, 805, 10.1002/art.39489 · DOI · Paper page
  66. Onal, 2012, Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss, J. Biol. Chem., 287, 29851, 10.1074/jbc.M112.377945 · DOI · Paper page
  67. Ota, 2016, Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis, Arthritis Res. Ther., 18, 67, 10.1186/s13075-016-0957-6 · DOI
  68. James, 2014, Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy, Arthritis Rheum., 66, 1712, 10.1002/art.38637 · DOI · Paper page
  69. Yamada, 2008, Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis, Ann. Rheum. Dis., 67, 1299, 10.1136/ard.2007.080341 · DOI · Paper page
  70. Yellin, 2012, A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis, Arthritis Rheum., 64, 1730, 10.1002/art.34330 · DOI · Paper page
  71. Banko, 2017, Induction and differentiation of IL-10-producing regulatory B cells from healthy blood donors and rheumatoid arthritis patients, J. Immunol., 198, 1512, 10.4049/jimmunol.1600218 · DOI · Paper page
  72. Wilson, 2012, Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG, J. Immunol., 188, 4741, 10.4049/jimmunol.1102651 · DOI · Paper page
  73. Yeo, 2015, Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis, Ann. Rheum. Dis., 74, 928, 10.1136/annrheumdis-2013-204116 · DOI · Paper page
  74. Amara, 2017, B cells expressing the IgA receptor FcRL4 participate in the autoimmune response in patients with rheumatoid arthritis, J. Autoimmun., 81, 34, 10.1016/j.jaut.2017.03.004 · DOI
  75. Ehrhardt, 2005, Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells, J. Exp. Med., 202, 783, 10.1084/jem.20050879 · DOI · Paper page
  76. Olalekan, 2015, B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis, Eur. J. Immunol., 45, 988, 10.1002/eji.201445036 · DOI · Paper page
  77. Hamel, 2014, B cell-specific expression of inducible costimulator ligand is necessary for the induction of arthritis in mice, Arthritis Rheum., 66, 60, 10.1002/art.38207 · DOI
  78. Crotty, 2011, Follicular helper CD4 T cells (TFH), Annu. Rev. Immunol., 29, 621, 10.1146/annurev-immunol-031210-101400 · DOI · Paper page
  79. O'Neill, 2007, Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis, J. Immunol., 179, 5109, 10.4049/jimmunol.179.8.5109 · DOI
  80. Lee, 2012, Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers, Immunity, 37, 880, 10.1016/j.immuni.2012.10.010 · DOI · Paper page
  81. Carter, 2012, Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis, Arthritis Res. Ther., 14, R32, 10.1186/ar3736 · DOI · Paper page
  82. Carter, 2011, Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells, J. Immunol., 186, 5569, 10.4049/jimmunol.1100284 · DOI · Paper page
  83. Daien, 2014, Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity, Arthritis Rheum., 66, 2037, 10.1002/art.38666 · DOI · Paper page
  84. Liu, 2014, TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells, Eur. J. Immunol., 44, 2121, 10.1002/eji.201344341 · DOI
  85. Ettinger, 2005, IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells, J. Immunol., 175, 7867, 10.4049/jimmunol.175.12.7867 · DOI · Paper page
  86. Rasmussen, 2016, Helper cells and IL-21 in rheumatic diseases, Dan Med. J., 63
  87. Fillatreau, 2015, Regulatory plasma cells, Curr. Opin. Pharmacol., 23, 1, 10.1016/j.coph.2015.04.006 · DOI
  88. Ries, 2014, B-type suppression: a role played by “regulatory B cells” or “regulatory plasma cells”, Eur. J. Immunol., 44, 1251, 10.1002/eji.201343683 · DOI
  89. Leandro, 2013, B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies, Arthritis Res. Ther., 15, S3, 10.1186/ar3908 · DOI · Paper page
  90. Kamburova, 2013, A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function, Am. J. Transplant., 13, 1503, 10.1111/ajt.12220 · DOI · Paper page
  91. Vancsa, 2013, Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion, J. Rheumatol., 40, 565, 10.3899/jrheum.111488 · doi:10.3899/jrheum.111488
  92. Tak, 2012, Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, Arthritis Rheum., 64, 360, 10.1002/art.33353 · DOI

Cited by

See all 68

Metadata

Authors
Fillatreau, S.
Venue
Clinical Immunology
Publisher
Elsevier BV
Published
2018-01
Volume
186
Pages
26-31
ISSN
1521-6616 (ISSN-L)
OpenAlex
W2738499080
Cited by
68
References
10
FWCI
1.67
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • European Research Council (647696)
  • Agence Nationale de la recherche (ANR-16-CE18-0007-01)
  • ABIR (031A403)
  • Deutsche Forschungsgemeinschaft (TRR130, FI 1238/1-2)
  • Bundesministerium für Bildung und Forschung (BMBF Neu2 16GW0069)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.